Search Results - Summary Record

The Statute For Developing Biotechnological New Pharmaceuticals Enterprises contains 13 articles and was promulgated by the President on 4 July 2007.The essential points are:
1) To provide for the goals of enacting this statute (Article 1)
2) To provide for the application of laws for developing biotechnological new pharmaceuticals enterprises (Article 2)
3) To define the terms referred to under this statute (Article 3)
4) To specify that the Ministry of Economic Affairs shall be the competent authority of this statute (Article 4)
5) To specify that business income tax shall be deductible within certain limited amount of expenditures for a biotechnological new pharmaceuticals company who has invested in research and development, and cultivation of talent (Article 5)
6) To specify that in order to encourage local businesses with proprietary capital and venture businesses to invest in the establishment or expansion of the biotechnological company, registered shareholders may be business income tax deductible on yearly basis within certain years (Article 6)
7) To specify that income tax may be imposed on a biotechnological new pharmaceuticals company's high ranking professional and technology investor who have acquired newly issued certificate of securities for technology share only when these securities have been assigned (Article 7)
8) To provide for the matters regarding the issuance proceedings, purchase price and taxation when a biotechnological new pharmaceuticals company issues the certificate of subscribing stock shares to high ranking professionals and technology investors (Article 8)
9) To specify that a technology assistance unit founded by government's donation shall cooperate and provide technological assistance in order to reinforce the technology induction and transfer for biotechnology and new pharmaceuticals (Article 9)
10) To specify that if a newly invented biotechnological new pharmaceuticals company's major technology provider is a government research institute's researcher, who may possess certain proportion of stock shares, serve as a board director or technology consultant, that the Government Employees Service Law shall be inapplicable (Article 10)
11) To specify that with the consent of an academic research institution, R and D personnel may serve as a biotechnological new pharmaceuticals company's R and D consultant or advisor (Article 11)
12) To specify that the government agencies concerned shall enact regulations governing the process of screening the biotechnological new pharmaceuticals products, that this process shall be open and transparent, and the screening system shall be unitary (Article 12)
13) To provide for the effective period of this statute. (Article 13)(13 provisions, p.19-23)